Semax Half-Life: The Honest Answer Is Unknown

The Semax half-life has never been measured in people. The most direct study followed Semax in rats: it reached brain tissue within two minutes and then broke down quickly. The study did not calculate a half-life. So the tidy numbers repeated online should not be treated as established human facts.

That answer can feel unsatisfying, but it clears up an important mix-up. Half-life means the time needed for the body to remove half of a substance. It is not automatically the same as how long someone notices an effect.

Why the Semax half-life is still unknown

Semax is a synthetic peptide, a short chain of seven amino acids, based on part of adrenocorticotropic hormone (ACTH), a pituitary hormone involved in the body's cortisol response. Published human work has mostly used Semax intranasally, meaning through the nose. None of that work produced the repeated blood measurements needed to calculate a human half-life.

As of September 9, 2026, the day this article was written, FDA's newest public Semax evidence review, prepared May 11 for its July 23–24 Pharmacy Compounding Advisory Committee meeting, said the agency found no human pharmacokinetic study of Semax free base or Semax acetate, two chemical forms reviewed for compounding, by any route. Pharmacokinetics means how a substance enters, moves through, and leaves the body. Compounding is pharmacy preparation of an individualized prescription. The FDA meeting page also makes clear that committee recommendations are nonbinding. The review did not create the missing measurement.

What the Semax studies actually measured

The clearest direct timing study used radioactively labeled Semax in rats. After one intranasal dose, researchers found 0.093% of the administered radioactivity per gram of brain tissue at two minutes. About 80% of that signal was intact Semax; the rest came from metabolites, the smaller pieces left as the peptide breaks down. The paper described rapid enzymatic degradation and said Pro-Gly-Pro became the main breakdown product in biological samples (Shevchenko et al., Russian Journal of Bioorganic Chemistry 2006).

Those details show quick arrival and quick breakdown in rats. They do not show that Semax has a two-minute half-life, and they cannot tell us how long it stays in a person's blood or brain. The study's two-minute mark was a sampling time, not a half-life result.

A second number sometimes gets attached to Semax, but it belongs to the related ACTH(4–10) fragment. In a study of eight healthy men, that fragment had two very short phases after a dose given through a vein: about 0.39 minutes and 3.84 minutes. As a nasal spray, its absorption into blood was low and variable, with a maximum bioavailability of 7.6%; bioavailability is the share of a dose that reaches circulation intact (Bickel et al., European Journal of Clinical Pharmacology 1988). Semax has a different ending, so borrowing those figures would be like timing a close relative and calling it the same person.

Why an effect can outlast the peptide in blood

A substance can start a signal and then disappear while that signal continues. That is the difference between pharmacokinetics and pharmacodynamics, which means what a substance does to the body. A light switch does not need a finger resting on it for the room to stay bright.

Semax research gives a few examples, all with limits. One rat study measured changes in BDNF and NGF gene activity one hour after a single intranasal dose. BDNF and NGF are proteins involved in nerve-cell maintenance and signaling. The changes varied by brain region, and the experiment did not measure a person's focus, memory, or felt duration (Agapova et al., Neuroscience Letters 2007).

Another rodent study found that a serotonin breakdown marker rose over one to four hours after Semax was injected into the abdomen. The route was not nasal, and the marker was not a cognitive outcome (Eremin et al., Neurochemical Research 2005). These experiments show why biological timing may run longer than blood exposure. They do not prove a set number of noticeable hours in humans. For the fuller mechanism story, see how Semax works.

Does N-acetyl Semax amidate last longer?

The modified form is often described as longer lasting because chemical caps are added to both ends of the peptide. That is a plausible stability idea, not a measured human duration. No peer-reviewed human study has compared its half-life with standard Semax.

The distinction matters because Semax acetate is also not the same molecule as N-acetyl Semax amidate. The guide to N-acetyl Semax amidate explains the chemistry and the evidence gap without assigning it an unsupported clock.

Route and formulation change the answer

The published timing evidence above concerns single-agent Semax, mostly given through the nose. Promise currently offers Semax / Selank, a combined injectable product; standard Semax by itself remains a waitlist product. No human study has measured how long Semax stays in the body after a subcutaneous injection, meaning an injection into the fatty layer under the skin, or isolated its timing inside this blend.

That means a nasal-study estimate cannot quietly become an injection schedule. The prescribed timing belongs to the exact formulation and the person receiving it, and a clinician should not have to guess from a vendor's half-life graphic.

Semax has never had a U.S. FDA-approved product, and the compounded formulation offered here is not FDA-approved. FDA review status is one fact in a clinical decision, not a warning or a marketing gate. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

What a prescription should settle

A useful plan should name the exact formulation, route, timing, and point for reassessment. It should also be honest that neither a blood half-life nor a reliable window of focus is available from human evidence. Feeling something for an afternoon would not prove the peptide remained in the blood for an afternoon.

At Promise, a licensed provider reviews every request and not everyone qualifies. That review is where the thin evidence, current medications, health history, and the reason for considering the blend are weighed together.